Blase N Polite

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE)
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637 1470, USA
    Cancer 118:1083-90. 2012
  2. ncbi Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B
    Blase N Polite
    The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 26:2659-65. 2008
  3. ncbi Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Med Clin North Am 89:771-93. 2005
  4. ncbi Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Cancer 106:923-30. 2006
  5. ncbi Colorectal cancer model of health disparities: understanding mortality differences in minority populations
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    J Clin Oncol 24:2179-87. 2006
  6. ncbi Breast cancer and race: a rising tide does not lift all boats equally
    Blase N Polite
    Section of Hematology/Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Perspect Biol Med 48:S166-75. 2005
  7. ncbi Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution
    BROOKE E SYLVESTER
    Center for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 18:350-9. 2012
  8. ncbi Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
    Manish R Sharma
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Invest New Drugs 30:1211-5. 2012
  9. ncbi Triple-negative breast cancers: a view from 10,000 feet
    Mandira Ray
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Cancer J 16:17-22. 2010
  10. ncbi Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer
    James J Dignam
    Department of Health Studies, 5841 South Maryland Ave, MC 2007, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 98:1647-54. 2006

Detail Information

Publications12

  1. ncbi Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE)
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637 1470, USA
    Cancer 118:1083-90. 2012
    ..In this analysis, the authors examined racial differences in clinical outcomes among patients with metastatic colorectal cancer (mCRC) who received bevacizumab...
  2. ncbi Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B
    Blase N Polite
    The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 26:2659-65. 2008
    ..This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials...
  3. ncbi Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Med Clin North Am 89:771-93. 2005
    ..The task now becomes to continue to understand the reasons for the disparities and ultimately to come up with workable solutions so that the amazing progress in CRC treatment benefits all groups in this country...
  4. ncbi Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Cancer 106:923-30. 2006
    ..Multiple epidemiologic studies have reported associations between venous thromboembolic events and subsequent cancer diagnoses, but the published results have not suggested clear cancer screening approaches...
  5. ncbi Colorectal cancer model of health disparities: understanding mortality differences in minority populations
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    J Clin Oncol 24:2179-87. 2006
    ..Finally, areas of ongoing and future research and policy initiatives aimed at reducing disparities are discussed...
  6. ncbi Breast cancer and race: a rising tide does not lift all boats equally
    Blase N Polite
    Section of Hematology/Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Perspect Biol Med 48:S166-75. 2005
    ..This paper discusses the factors that may contribute to differences in survival and differences in stage at diagnosis between African American and white women...
  7. ncbi Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution
    BROOKE E SYLVESTER
    Center for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 18:350-9. 2012
    ....
  8. ncbi Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
    Manish R Sharma
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Invest New Drugs 30:1211-5. 2012
    ..Dasatinib, an oral inhibitor of Src family kinases, inhibits proliferation in CRC cell lines and has antitumor activity in CRC xenograft models...
  9. ncbi Triple-negative breast cancers: a view from 10,000 feet
    Mandira Ray
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Cancer J 16:17-22. 2010
    ..Variations in risk factors and socioeconomic status, lack of treatment, delays in treatment, and inadequate dosing of chemotherapy are just a few of the many reasons that may explain why this incidence and survival disparity persists...
  10. ncbi Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer
    James J Dignam
    Department of Health Studies, 5841 South Maryland Ave, MC 2007, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 98:1647-54. 2006
    ..We investigated the association of body mass index (BMI) with outcomes after colon cancer in patients from cooperative group clinical trials...
  11. ncbi Infused chemotherapy use in the elderly after patent expiration
    Rena M Conti
    The University of Chicago, IL 60637, USA
    Am J Manag Care 18:e173-8. 2012
    ..The use of anticancer drugs (chemotherapies) is an important determinant of national spending trends. Recent policies have aimed to accelerate generic entry among chemotherapies to generate cost savings...
  12. ncbi Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial
    Blase N Polite
    Section of Hematology-Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 4:275-80. 2006
    ..CONCLUSION: Based on a response rate of only 6%, a median TTP of 2 months, and significant toxicities, further study of IFN-alpha in combination with imatinib mesylate is not recommended in patients with metastatic RCC...